142 related articles for article (PubMed ID: 16924354)
1. Fluoroquinolones may delay the diagnosis of tuberculosis.
Ang D; Hsu AA; Tan BH
Singapore Med J; 2006 Sep; 47(9):747-51. PubMed ID: 16924354
[TBL] [Abstract][Full Text] [Related]
2. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis.
Long R; Chong H; Hoeppner V; Shanmuganathan H; Kowalewska-Grochowska K; Shandro C; Manfreda J; Senthilselvan A; Elzainy A; Marrie T
Clin Infect Dis; 2009 May; 48(10):1354-60. PubMed ID: 19348594
[TBL] [Abstract][Full Text] [Related]
3. Fluoroquinolone resistance in renal isolates of Mycobacterium tuberculosis.
Webster D; Long R; Shandro C; Pettipas J; Leblanc J; Davidson R; Fanning A
Int J Tuberc Lung Dis; 2010 Feb; 14(2):217-22. PubMed ID: 20074414
[TBL] [Abstract][Full Text] [Related]
4. Resistance to fluoroquinolones and treatment failure/short-term relapse of community-acquired urinary tract infections caused by Escherichia coli.
Gagliotti C; Buttazzi R; Sforza S; Moro ML;
J Infect; 2008 Sep; 57(3):179-84. PubMed ID: 18707763
[TBL] [Abstract][Full Text] [Related]
5. Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions.
Shen GH; Tsao TC; Kao SJ; Lee JJ; Chen YH; Hsieh WC; Hsu GJ; Hsu YT; Huang CT; Lau YJ; Tsao SM; Hsueh PR
Int J Antimicrob Agents; 2012 Mar; 39(3):201-5. PubMed ID: 22285045
[TBL] [Abstract][Full Text] [Related]
6. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia.
Yoon YS; Lee HJ; Yoon HI; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
Int J Tuberc Lung Dis; 2005 Nov; 9(11):1215-9. PubMed ID: 16333927
[TBL] [Abstract][Full Text] [Related]
7. Think TB! Is the diagnosis of pulmonary tuberculosis delayed by the use of antibiotics?
Craig SE; Bettinson H; Sabin CA; Gillespie SH; Lipman MC
Int J Tuberc Lung Dis; 2009 Feb; 13(2):208-13. PubMed ID: 19146749
[TBL] [Abstract][Full Text] [Related]
8. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis.
Dooley KE; Golub J; Goes FS; Merz WG; Sterling TR
Clin Infect Dis; 2002 Jun; 34(12):1607-12. PubMed ID: 12032896
[TBL] [Abstract][Full Text] [Related]
9. Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones.
Grossman RF; Hsueh PR; Gillespie SH; Blasi F
Int J Infect Dis; 2014 Jan; 18():14-21. PubMed ID: 24211230
[TBL] [Abstract][Full Text] [Related]
10. Analyses of fluoroquinolones and Clostridium difficile-associated diarrhoea in tuberculosis patients.
Chang KC; Leung CC; Yew WW; Lam FM; Ho PL; Chau CH; Cheng VC; Yuen KY
Int J Tuberc Lung Dis; 2009 Mar; 13(3):341-6. PubMed ID: 19275794
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary tuberculosis presenting as community-acquired pneumonia.
Asnis DS; Cherian S; Sun T; Shrestha S; Santucci T
Clin Infect Dis; 2002 Dec; 35(12):1574-5. PubMed ID: 12471584
[No Abstract] [Full Text] [Related]
12. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
[TBL] [Abstract][Full Text] [Related]
13. Use of fluoroquinolone antibiotics leads to tuberculosis treatment delay in a South African gold mining community.
Jeon CY; Calver AD; Victor TC; Warren RM; Shin SS; Murray MB
Int J Tuberc Lung Dis; 2011 Jan; 15(1):77-83. PubMed ID: 21276301
[TBL] [Abstract][Full Text] [Related]
14. Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease.
Gaba PD; Haley C; Griffin MR; Mitchel E; Warkentin J; Holt E; Baggett P; Sterling TR
Arch Intern Med; 2007 Nov; 167(21):2317-22. PubMed ID: 18039990
[TBL] [Abstract][Full Text] [Related]
15. [Bone and joint tuberculosis concurrent with tuberculosis of other organs].
Yagi O; Kawabe Y; Nagayama N; Shimada M; Kawashima M; Kaneko Y; Ariga H; Ohshima N; Matsui Y; Suzuki J; Masuda K; Tamura A; Nagai H; Akagawa S; Machida K; Kurashima A; Nakajima Y; Yotsumoto H
Kekkaku; 2007 Jun; 82(6):523-9. PubMed ID: 17633120
[TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolones for treatment of community-acquired pneumonia and tuberculosis: putting the risk of resistance into perspective.
Low DE
Clin Infect Dis; 2009 May; 48(10):1361-3. PubMed ID: 19348596
[No Abstract] [Full Text] [Related]
17. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
18. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens.
Ho CC; Chen YC; Hu FC; Yu CJ; Yang PC; Luh KT
Clin Infect Dis; 2009 Jun; 48(11):1526-33. PubMed ID: 19400686
[TBL] [Abstract][Full Text] [Related]
19. Drug abuse profile - patient delay, diagnosis delay and drug resistance pattern - among addict patients with tuberculosis.
Shamaei M; Marjani M; Baghaei P; Chitsaz E; Rezaei Tabar E; Abrishami Z; Tabarsi P; Mansouri D; Masjedi MR
Int J STD AIDS; 2009 May; 20(5):320-3. PubMed ID: 19386968
[TBL] [Abstract][Full Text] [Related]
20. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
